Free Trial
NASDAQ:PASG

Passage Bio Q4 2024 Earnings Report

Passage Bio logo
$0.32 0.00 (-0.92%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.33 +0.01 (+1.55%)
As of 04/25/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Passage Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Passage Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 4, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Passage Bio's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Sunday, May 11, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Passage Bio Earnings Headlines

From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
See More Passage Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Passage Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Passage Bio and other key companies, straight to your email.

About Passage Bio

Passage Bio (NASDAQ:PASG), a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

View Passage Bio Profile

More Earnings Resources from MarketBeat